These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis. Sanchorawala V; Wright DG; Seldin DC; Dember LM; Finn K; Falk RH; Berk J; Quillen K; Skinner M Bone Marrow Transplant; 2001 Oct; 28(7):637-42. PubMed ID: 11704785 [TBL] [Abstract][Full Text] [Related]
16. Characteristics and long-term outcome of patients with systemic immunoglobulin light-chain amyloidosis. Nelson LM; Gustafsson F; Gimsing P Acta Haematol; 2015; 133(4):336-46. PubMed ID: 25531398 [TBL] [Abstract][Full Text] [Related]
17. High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study. Perz JB; Schonland SO; Hundemer M; Kristen AV; Dengler TJ; Zeier M; Linke RP; Ho AD; Goldschmidt H Br J Haematol; 2004 Dec; 127(5):543-51. PubMed ID: 15566357 [TBL] [Abstract][Full Text] [Related]
18. [A case of primary amyloidosis]. Ardashev VN; Potekhin NP; Rukavitsyn OA; Borisov AG; Malysheva SA Klin Med (Mosk); 2006; 84(6):56-9. PubMed ID: 16875072 [TBL] [Abstract][Full Text] [Related]
19. Current and emerging views and treatments of systemic immunoglobulin light-chain (Al) amyloidosis. Comenzo RL Contrib Nephrol; 2007; 153():195-210. PubMed ID: 17075231 [TBL] [Abstract][Full Text] [Related]
20. Marked and rapid regression of hepatic amyloid deposition in a patient with systemic light chain (AL) amyloidosis after high-dose melphalan therapy with stem cell transplantation. Katoh N; Matsushima A; Kurozumi M; Matsuda M; Ikeda S Intern Med; 2014; 53(17):1991-5. PubMed ID: 25175136 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]